UBE2Q1 (ubiquitin conjugating enzyme E2 Q1) is an E2 ubiquitin-conjugating enzyme that catalyzes covalent attachment of ubiquitin to target proteins 1. The enzyme contains a conserved E2 ubiquitin conjugating domain and a RWD domain 2. UBE2Q1 functions as an oncogenic protein through multiple mechanisms: it directly interacts with and promotes proteasomal degradation of p53, a key tumor suppressor 3, and also interacts with B4GALT1 to regulate cell adhesion 4. Clinically, UBE2Q1 is significantly overexpressed in multiple solid tumors including colorectal (74.42% of cases) 5, breast (61.9% of cases) 2, and hepatocellular carcinomas 6. Elevated UBE2Q1 expression correlates with enhanced cell proliferation, increased clonogenicity, cell cycle progression, and poor prognosis 76. UBE2Q1 knockdown inhibits cancer cell growth and increases p53 and p21 levels, demonstrating its functional importance 6. Additionally, UBE2Q1 has been identified as a prognostic biomarker in sepsis pathogenesis through ferritinophagy regulation 8. These findings establish UBE2Q1 as a potential therapeutic target and diagnostic tool across multiple cancers and inflammatory diseases.